CHEMOKINE REGULATION OF NKT CELLS, AND ACAID

NKT 细胞的趋化因子调节和 ACAID

基本信息

  • 批准号:
    6637202
  • 负责人:
  • 金额:
    $ 43.07万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2000
  • 资助国家:
    美国
  • 起止时间:
    2000-08-01 至 2005-07-31
  • 项目状态:
    已结题

项目摘要

Chemokines are associated with a variety of inflammatory and autoimmune diseases for their role in recruitment of cells to the sites of immune induction and inflammation. However, few studies have explored a role for chemokines in peripheral tolerance induction and no studies are reported for specific chemokines for NKT cells. This research plan will explore the role of specific chemokines in negative regulation of an immune inflammatory response and specifically in the recruitment of NKT cells to the site of tolerance induction. Anterior Chamber Associated Immune Deviation (ACAID) is associated with the selective negative regulation of delayed type hypersensitivity (DTH) after the introduction of antigen into the eye. An accumulation of splenic NKT cells is absolutely required for the development of ACAID. Preliminary data show that MIP-2 is associated with NKT cell recruitment. We will use molecular, cellular and morphological techniques to identify and define the role of the chemokines in the tolerance inducing process. Aim One will define the chemokine profile by RNase Protection Assay and multi-color flow cytometry. The second aim will use classic chemotaxis assays to define the migratory response of NKT cells to ACAID associated chemokines, along with molecular techniques to confirm the expression of chemokine receptors on these cells. The third aim will explore the mechanisms of chemokine-NKT cell interaction during ACAID induction by reconstituting NKT cell knockout mice with NKT cells from chemokine receptor knockout mice. A local adoptive transfer assay will measure if regulator T cells were generated. Finally, the fourth aim will explore the hypothesis that the cells recruited to the spleen for the induction of ACAID must necessarily form interactive cell clusters. After identifying such clusters and cells within, we will modulate chemokines and potential adhesion molecules and evaluate the outcome by quality and quantity of clusters. NKT cell defects and/or deficiency is associated with a variety of autoimmune disorders in both mice and humans (lupus, type 1 diabetes, systemic scleroderma). Thus, the mechanisms of NKT cell mediated induction of T regulatory cells might function in the maintenance of self tolerance in a variety of organs and tissues in addition to immune privileged sites such as the eye. The novel postulates about chemokines, innate cells and peripheral tolerance presented in this proposal, represent a heretofore totally unexplored area of research.
趋化因子与多种炎性和自身免疫性疾病相关,因为它们在将细胞募集到免疫诱导和炎症部位中起作用。 然而,很少有研究探讨了趋化因子在外周耐受诱导中的作用,也没有关于NKT细胞特异性趋化因子的研究报道。 这项研究计划将探讨特定趋化因子在免疫炎症反应的负调控中的作用,特别是在招募NKT细胞到耐受诱导部位中的作用。 前房相关免疫偏离(ACAID)与抗原进入眼内后迟发型超敏反应(DTH)的选择性负调节有关。 脾NKT细胞的积累是ACAID发展所必需的。初步数据显示MIP-2与NKT细胞募集相关。 我们将使用分子、细胞和形态学技术来鉴定和确定趋化因子在耐受诱导过程中的作用。 目的通过RNase保护试验和多色流式细胞术检测趋化因子的表达谱。 第二个目标将使用经典的趋化性测定来确定NKT细胞对ACAID相关趋化因子的迁移反应,沿着分子技术来确认这些细胞上趋化因子受体的表达。 第三个目标是通过用来自趋化因子受体敲除小鼠的NKT细胞重建NKT细胞敲除小鼠来探索趋化因子-NKT细胞相互作用在ACAID诱导过程中的机制。 局部过继转移测定将测量是否产生调节性T细胞。 最后,第四个目标将探讨这一假设,即招募到脾脏诱导ACAID的细胞必须形成相互作用的细胞簇。 在识别出这些簇和细胞后,我们将调节趋化因子和潜在的粘附分子,并通过簇的质量和数量来评估结果。 NKT细胞缺陷和/或缺乏与小鼠和人类中的多种自身免疫性疾病(狼疮、1型糖尿病、系统性硬皮病)相关。 因此,除了眼睛等免疫特权部位之外,NKT细胞介导的T调节细胞诱导机制可能还在维持多种器官和组织的自身耐受性方面发挥作用。 该提案中提出的关于趋化因子、先天细胞和外周耐受性的新假设代表了迄今为止完全未探索的研究领域。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Brain trauma impacts retinal processing: photoreceptor pathway interactions in traumatic light sensitivity.
  • DOI:
    10.1007/s10633-022-09871-1
  • 发表时间:
    2022-06
  • 期刊:
  • 影响因子:
    1.4
  • 作者:
    Tyler, Christopher W.;Likova, Lora T.
  • 通讯作者:
    Likova, Lora T.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Joan Stein-Streilein其他文献

Joan Stein-Streilein的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Joan Stein-Streilein', 18)}}的其他基金

Mechanisms of Ocular Immune Privilege in the Posterior Eye
后眼的眼部免疫特权机制
  • 批准号:
    8047973
  • 财政年份:
    2010
  • 资助金额:
    $ 43.07万
  • 项目类别:
Mechanisms of Ocular Immune Privilege in the Posterior Eye
后眼的眼部免疫特权机制
  • 批准号:
    7872399
  • 财政年份:
    2010
  • 资助金额:
    $ 43.07万
  • 项目类别:
Adaptive and innate regulation of immuneprivilege
免疫特权的适应性和先天调节
  • 批准号:
    7388130
  • 财政年份:
    2006
  • 资助金额:
    $ 43.07万
  • 项目类别:
Adaptive and innate regulation of immuneprivilege
免疫特权的适应性和先天调节
  • 批准号:
    7195014
  • 财政年份:
    2006
  • 资助金额:
    $ 43.07万
  • 项目类别:
Adaptive and innate regulation of immune privilege
免疫豁免的适应性和先天调节
  • 批准号:
    7618420
  • 财政年份:
    2006
  • 资助金额:
    $ 43.07万
  • 项目类别:
Adaptive and innate regulation of immune privilege.
免疫特权的适应性和先天调节。
  • 批准号:
    7093212
  • 财政年份:
    2006
  • 资助金额:
    $ 43.07万
  • 项目类别:
Adaptive and innate regulation of immune privilege.
免疫特权的适应性和先天调节。
  • 批准号:
    7568382
  • 财政年份:
    2006
  • 资助金额:
    $ 43.07万
  • 项目类别:
Adaptive and innate regulation of immune privilege
免疫豁免的适应性和先天调节
  • 批准号:
    8114426
  • 财政年份:
    2006
  • 资助金额:
    $ 43.07万
  • 项目类别:
HARVARD PROGRAM IN OCULAR IMMUNOLOGY
哈佛大学眼免疫学项目
  • 批准号:
    6950383
  • 财政年份:
    2000
  • 资助金额:
    $ 43.07万
  • 项目类别:
CHEMOKINE REGULATION OF NKT CELLS, AND ACAID
NKT 细胞的趋化因子调节和 ACAID
  • 批准号:
    6525048
  • 财政年份:
    2000
  • 资助金额:
    $ 43.07万
  • 项目类别:

相似海外基金

How do cytokine receptors transmit signals?
细胞因子受体如何传递信号?
  • 批准号:
    DP230102422
  • 财政年份:
    2023
  • 资助金额:
    $ 43.07万
  • 项目类别:
    Discovery Projects
Protein Translation Control of Cytokine Receptors
细胞因子受体的蛋白质翻译控制
  • 批准号:
    RGPIN-2018-04852
  • 财政年份:
    2022
  • 资助金额:
    $ 43.07万
  • 项目类别:
    Discovery Grants Program - Individual
Deciphering novel cross-talk between innate cytokine receptors
破译先天细胞因子受体之间的新型串扰
  • 批准号:
    DP210103122
  • 财政年份:
    2021
  • 资助金额:
    $ 43.07万
  • 项目类别:
    Discovery Projects
Protein Translation Control of Cytokine Receptors
细胞因子受体的蛋白质翻译控制
  • 批准号:
    RGPIN-2018-04852
  • 财政年份:
    2021
  • 资助金额:
    $ 43.07万
  • 项目类别:
    Discovery Grants Program - Individual
Protein Translation Control of Cytokine Receptors
细胞因子受体的蛋白质翻译控制
  • 批准号:
    RGPIN-2018-04852
  • 财政年份:
    2020
  • 资助金额:
    $ 43.07万
  • 项目类别:
    Discovery Grants Program - Individual
Protein Translation Control of Cytokine Receptors
细胞因子受体的蛋白质翻译控制
  • 批准号:
    RGPIN-2018-04852
  • 财政年份:
    2019
  • 资助金额:
    $ 43.07万
  • 项目类别:
    Discovery Grants Program - Individual
A dissection of transmembrane signal transduction and downstream signaling response in cytokine receptors
细胞因子受体跨膜信号转导和下游信号反应的剖析
  • 批准号:
    412345
  • 财政年份:
    2019
  • 资助金额:
    $ 43.07万
  • 项目类别:
    Fellowship Programs
Protein Translation Control of Cytokine Receptors
细胞因子受体的蛋白质翻译控制
  • 批准号:
    RGPIN-2018-04852
  • 财政年份:
    2018
  • 资助金额:
    $ 43.07万
  • 项目类别:
    Discovery Grants Program - Individual
Development of analysis method of inflammation-related proteins in serum using inflammatory cytokine receptors
开发利用炎症细胞因子受体分析血清中炎症相关蛋白的方法
  • 批准号:
    17K18360
  • 财政年份:
    2017
  • 资助金额:
    $ 43.07万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Mutations and single nucleotide polymorphisms of cytokine receptors in Kawasaki disease
川崎病细胞因子受体突变及单核苷酸多态性
  • 批准号:
    16K10020
  • 财政年份:
    2016
  • 资助金额:
    $ 43.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了